Risk factors for early death in patients undergoing treatment for multiple myeloma

Annals of Hematology

Volumn 80, Issue 8, 2001, Pages 452-455

  Murakami, H ^a   Hayashi, K ^a   Hatsumi, N ^a   Saitoh, T ^a   Yokohama, A ^a   Matsushima, T ^a   Tsukamoto, N ^a   Morita, K ^a   Karasawa, M ^a   Ogawara, H ^a   Sawamura, M ^a   Nojima, Y ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Beta 2 microglobulin; Early death; Myeloma; Prognosis

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISOLONE; RANIMUSTINE; VINCRISTINE;

ACCURACY; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; HUMAN; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 17944378321     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770100330     Document Type: Article

References (16)

1. Treatment of multiple myeloma. Combination chemotherapy with different melphalan dose regimens
2. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
3. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma
4. High serum lactate dehydrogenase levels as a marker for drug resistance and short survival in multiple myeloma
5. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy
6. Staging and kinetics of multiple myeloma
7. A clinical staging system for multiple myeloma
8. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
9. Multiple myeloma: Significance of plasmablastic subtype in morphological classification
10. Double-intensive therapy in high-risk multiple myeloma
11. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation
12. A staging system for multiple myeloma based on the morphology of myeloma cells
13. Bcl-2 protein expression is not related to short survival in multiple myeloma
14. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma
15. Autotransplants in multiple myeloma: What have we learned?